Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Free Report)’s stock price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.65 and traded as high as $0.90. Brainstorm Cell Therapeutics shares last traded at $0.87, with a volume of 9,450 shares.
Brainstorm Cell Therapeutics Stock Performance
The firm has a market capitalization of $9.60 million, a PE ratio of -0.26 and a beta of 0.69. The company has a fifty day moving average price of $0.68 and a 200-day moving average price of $0.65.
About Brainstorm Cell Therapeutics
BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI) is a clinical‐stage biotechnology company focused on developing autologous cell therapies for the treatment of neurodegenerative diseases. The company’s proprietary platform leverages mesenchymal stem cells (MSCs) that are engineered to secrete neurotrophic and growth factors designed to support neuronal survival and function.
The company’s lead product candidate, NurOwn, is an autologous MSC therapy currently in advanced clinical development for amyotrophic lateral sclerosis (ALS).
Read More
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
